Quick Answer
Nuvectis Pharma, Inc. reported R&D Expense of $18.15 million for fiscal year 2025.
Nuvectis Pharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $18.15M | +40.5% |
| 2024 | $12.92M | -16.0% |
| 2023 | $15.38M | +16.3% |
| 2022 | $13.23M | +38.6% |
| 2021 | $9.54M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.77M | +104.8% | +59.8% |
| June 30, 2025 | $3.61M | +22.8% | -1.8% |
| March 31, 2025 | $3.68M | +38.3% | +30.5% |
| September 30, 2024 | $2.82M | -37.2% | -4.2% |
| June 30, 2024 | $2.94M | -30.9% | +10.6% |
| March 31, 2024 | $2.66M | +12.4% | -40.7% |
| September 30, 2023 | $4.49M | -0.8% | +5.3% |
| June 30, 2023 | $4.26M | +70.1% | +80.1% |
- Nuvectis Pharma, Inc. showed an increase of +40.5% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Nuvectis Pharma, Inc.’s r&d expense has grown by 90.2% (from $9.54 million to $18.15 million).
- The most recent figure is from Nuvectis Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: